EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to OptiEFAX™ and maintenance of normal blood LDL-cholesterol concentrations pursuant to Article 13(5) of Regulation (EC) No 1924/2006 by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on
the substantiation of a health claim related to OptiEFAX™ and maintenance of normal
blood LDL-cholesterol concentrations pursuant to Article 13(5) of Regulation (EC) No
1924/2006
EFSA Publication; Tetens, Inge
Link to article, DOI:
10.2903/j.efsa.2012.2802
Publication date:
2012
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA Publication (2012). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on
the substantiation of a health claim related to OptiEFAX™ and maintenance of normal blood LDL-cholesterol
concentrations pursuant to Article 13(5) of Regulation (EC) No 1924/2006. Parma, Italy: European Food Safety
Authority.  (The EFSA Journal; No. 2802, Vol. 10(7)). DOI: 10.2903/j.efsa.2012.2802
  EFSA Journal 2012;10(7):2802 
 
Suggested citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the 
substantiation of a health claim related to OptiEFAX™ and maintenance of normal blood LDL-cholesterol concentrations 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2012;10(7):2802. [8 pp.]. 
doi:10.2903/j.efsa.2012.2802. Available online: www.efsa.europa.eu/efsajournal 
 
 © European Food Safety Authority, 2012 
SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
OptiEFAX™ and maintenance of normal blood LDL-cholesterol 
concentrations pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Nutrilinks Sarl, submitted for authorisation of a claim pursuant to Article 13(5) of 
Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to OptiEFAX™ and maintenance of normal blood LDL-cholesterol concentrations. The food that is the 
subject of the health claim, OptiEFAX™, which is standardised pure krill oil, is sufficiently characterised in 
relation to the claimed effect. The claimed effect, maintenance of normal blood LDL-cholesterol concentrations, 
is a beneficial physiological effect. The target population proposed by the applicant is the general population. No 
human studies have been provided from which conclusions could be drawn for the scientific substantiation of the 
claim. A cause and effect relationship has not been established between the consumption of OptiEFAX™ and 
maintenance of normal blood LDL-cholesterol concentrations. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following an application from Nutrilinks Sarl, submitted for authorisation of a claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to OptiEFAX™ and maintenance of normal blood LDL-
cholesterol concentrations. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence.  
The food that is the subject of the health claim is OptiEFAX™, which is standardised pure krill oil. The 
Panel considers that the food, OptiEFAX™, which is the subject of the health claim, is sufficiently 
characterised in relation to the claimed effect. 
The claimed effect is maintenance of normal blood LDL-cholesterol concentrations. The target 
population proposed by the applicant is the general population. The Panel considers that maintenance 
of normal blood LDL-cholesterol concentrations is a beneficial physiological effect. 
One human intervention study was provided as pertinent to the claim. This was a 90-day, double-
blind, randomised, parallel study in which 120 subjects, some of whom were on lipid lowering 
medication throughout the study, were randomly assigned to consume daily either 2 or 3 g krill oil, 
1 or 1.5 g krill oil, 3 g of fish oil, or placebo. The Panel notes that the nature of the placebo was not 
reported, that no information about the baseline characteristics of groups with respect to medication 
use was provided, that medication use and repeated measures were not taken into account in the 
analysis and that the presentation of data and of the results from statistical analyses does not allow an 
interpretation of the results. The Panel considers that no conclusions can be drawn from this study for 
the scientific substantiation of the claim. 
The Panel notes that no human studies have been provided from which conclusions could be drawn 
for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of OptiEFAX™ and maintenance of normal blood LDL-cholesterol concentrations. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
in disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Art 13(3) shall be submitted by the applicant to the national competent 
authority of a Member State, which will make the application and any supplementary information 
supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 15/02/2012. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
 On 19/03/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 The applicant provided the missing information on 24/04/2012. 
 The scientific evaluation procedure started on 27/04/2012. 
 During its meeting on 27/06/2012, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to OptiEFAX™ and 
maintenance of normal blood LDL-cholesterol concentrations. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to OptiEFAX™ and maintenance of 
normal blood LDL-cholesterol concentrations. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of OptiEFAX™, a positive assessment of its safety, nor a decision on whether OptiEFAX™ is, 
or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Nutrilinks Sarl, Chemin de Beau-rivage 7, P.O. Box 96, CH-1000 
Lausanne 21, Switzerland. 
Food/constituent as stated by the applicant 
According to the applicant, the food, which is the subject of the claim, is OptiEFAX™, a standardised 
pure krill oil extract. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect relates to maintaining healthy blood levels of LDL 
cholesterol. 
Wording of the health claim as proposed by the applicant 
The following wordings are proposed by the applicant: “OptiEFAX™ helps to maintain healthy blood 
levels of LDL cholesterol”. 
Specific conditions of use as proposed by the applicant 
The applicant proposes the target population to be the general population and conditions of use of one 
capsule of a food supplement with 1 to 1.5 g of the standardised pure krill oil containing defined 
minimal amount of omega-3 fatty acids, specifically EPA and DHA, provided in soft or a hard capsule 
with water, preferably in the morning, during 90 consecutive days. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is OptiEFAX™, which is standardised pure krill oil. 
Krill oil is oil, which is extracted from the crustacean Euphausia superba (Antarctic Krill). It has 
been authorised as novel food ingredient
5
. The krill oil, which is the subject of the claim, complies 
with Commission Decision 2009/752/EC. The main fatty acids contained in the krill oil, which is the 
subject of the claim, are eicosapentaenoic acid (EPA, C20:5, 22 %), palmitic acid (C16:0, 20 %), 
docosahexaenoic acid (DHA, C22:6, 13 %), oleic acid (C18:1 n-9, 10 %), myristic acid (C14:0, 9 %), 
and vaccenic acid (C18:1 n-7, 7 %). The content of esterified astaxanthin amounts to around 1,000 to 
1,500 mg/kg. Fatty acids and astaxanthin can be measured in foods by established methods. 
Information on the stability and the batch-to-batch variability of the product has been provided. 
The Panel considers that the food, OptiEFAX™, which is the subject of the health claim, is sufficiently 
characterised in relation to the claimed effect. 
                                                     
5  2009/752/EC: Commission Decision of 12 October 2009 authorising the placing on the market of a lipid extract from 
Antarctic Krill Euphausia superba as a novel food ingredient under Regulation (EC) No 258/97 of the European 
Parliament and of the Council (notified under document C(2009) 7647), OJ L 268, 13.10.2009, p. 33–34. 
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2. Relevance of the claimed effect to human health 
The claimed effect is maintenance of normal LDL-cholesterol concentrations. The target population 
proposed by the applicant is the general population. 
Low-density lipoproteins (LDL) carry cholesterol from the liver to peripheral tissues, including the 
arteries. Elevated LDL-cholesterol, by convention >160 mg/dL (>4.1 mmol/L), may compromise the 
normal structure and function of the arteries. 
The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in Pubmed, ScienceDirect, Blackwell Synergy, Wiley 
InterScience, Mary Ann Liebert, Scirus, IBIDS, SciFinder Scholar, Pascal, Google and SCOPUS with 
the search terms [“Neptune krill oil”] AND [“cholesterol”] for publications between January 2000 to 
May 2011. Hand searches in specialised libraries and web research were also performed. Upon 
request from EFSA during the validation period of the application, the applicant extended the 
literature search to cover also krill oils other than those manufactured according to the applicant’s 
specifications.  
This literature search resulted in the identification of three human intervention studies (Bunea et al., 
2004; Maki et al., 2009; Ulven et al., 2011), two of which (Maki et al., 2009; Ulven et al., 2011) were 
not considered pertinent to the claim by the applicant owing to compositional differences in EPA and 
DHA content of the krill oils administered in these studies, the absence of information about the 
amount of astaxanthin in the interventions and the study design.  
The study by Bunea et al. (2004) was a 90-day, double-blind, randomised, parallel study in which 
120 subjects (m/f ratio not reported) with elevated blood cholesterol and triglyceride concentrations 
were randomly assigned to consume daily either 2 or 3 g krill oil (group A: n=30, 2 g: n=19, 3 g: 
n=11, dose based on BMI), 1 or 1.5 g krill oil (group B: n=30, 1 g: n=23, 1.5 g: n=7, dose based on 
BMI), 3 g of fish oil (group C: n=not reported) or placebo (group D: n=not reported, nature of placebo 
not reported). The krill oil administered in the study was manufactured in line with the applicant’s 
specifications. Subjects were allowed to continue lipid lowering medication throughout the study 
(n per group not reported). It was estimated that a sample size of 30 subjects per group was needed to 
detect a 15 % change from baseline in total cholesterol with 90 % power. Blood lipids were measured 
at baseline and at 30 and 90 days of the study. No information about drop-outs has been provided in 
the publication. Data were analysed using one-way analysis of variance. Results have been given 
without indication of dispersion measures and between-group comparisons have been reported 
without any indication of the significance level obtained. The Panel notes that the nature of the 
placebo was not reported, that no information about the baseline characteristics of groups with respect 
to medication use was provided, that medication use and repeated measures were not taken into 
account in the analysis and that the presentation of data and of the results from statistical analyses 
does not allow an interpretation of the results. The Panel considers that no conclusions can be drawn 
from this study for the scientific substantiation of the claim. 
The Panel notes that no human studies have been provided from which conclusions could be drawn 
for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of OptiEFAX™ and maintenance of normal blood LDL-cholesterol concentrations.  
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CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, OptiEFAX™, which is standardised pure krill oil and subject of the claim, is 
sufficiently characterised in relation to the claimed effect.  
 Maintenance of normal blood LDL-cholesterol concentrations is a beneficial physiological 
effect. 
 A cause and effect relationship has not been established between the consumption of 
OptiEFAX™ and maintenance of normal blood LDL-cholesterol concentrations. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on OptiEFAX™ and maintenance of normal LDL-cholesterol concentrations 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0334_BE). April 2012. 
Submitted by Nutrilinks Sarl. 
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GLOSSARY AND ABBREVIATIONS 
BMI Body mass index 
DHA Docosahexaenoic acid 
EPA Eicosapentaenoic acid 
LDL Low-density lipoproteins 
